Li Kang Biomedical Co Ltd Total Assets
Li Kang Biomedical Co Ltd total assets. Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) holds total assets worth NT$1.09 Billion TWD (≈ $34.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Li Kang Biomedical Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Li Kang Biomedical Co Ltd (2002–2025)
Total assets of Li Kang Biomedical Co Ltd from 2002 to 2025. This chart illustrates how Li Kang Biomedical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 6242 share price today for real-time trading data and today's change.
Li Kang Biomedical Co Ltd - Asset Composition Analysis
Li Kang Biomedical Co Ltd Total Assets Breakdown (December 2025)
Li Kang Biomedical Co Ltd total assets breakdown as of December 2025. Li Kang Biomedical Co Ltd's total assets of NT$1.09 Billion consist of 23.2% current assets and 76.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 3.9% |
| Accounts Receivable | NT$9.33 Million | 0.9% |
| Inventory | NT$45.79 Million | 4.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Li Kang Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Li Kang Biomedical Co Ltd (6242) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Li Kang Biomedical Co Ltd's current assets represent 23.2% of total assets in 2025, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, down from 4.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 4.2% of total assets.
Li Kang Biomedical Co Ltd Competitors by Total Assets
Key competitors of Li Kang Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royal Caribbean Cruises Ltd
NYSE:RCL
|
USA | $44.64 Billion |
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH
|
USA | $23.79 Billion |
|
Rainbow Tours SA
WAR:RBW
|
Poland | zł1.62 Billion |
|
Corporate Travel Management Ltd
AU:CTD
|
Australia | AU$1.59 Billion |
|
Aviation Links Ltd
TA:AVIA
|
Israel | ILA107.54 Million |
|
Flight Centre Travel Group Ltd
AU:FLT
|
Australia | AU$4.66 Billion |
|
WEB Travel Group Ltd
AU:WEB
|
Australia | AU$1.54 Billion |
|
Helloworld Travel Ltd
AU:HLO
|
Australia | AU$596.98 Million |
Li Kang Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 3.84 | 1.71 |
| Quick Ratio | 1.24 | 3.47 | 1.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$90.43 Million | NT$381.88 Million | NT$98.16 Million |
Li Kang Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Li Kang Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | NT$1.09 Billion |
| Market Capitalization | $32.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Li Kang Biomedical Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Li Kang Biomedical Co Ltd's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual total assets of Li Kang Biomedical Co Ltd from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.09 Billion ≈ $34.44 Million |
+5.55% |
| 2024-12-31 | NT$1.04 Billion ≈ $32.63 Million |
+25.22% |
| 2023-12-31 | NT$827.00 Million ≈ $26.06 Million |
+20.06% |
| 2022-12-31 | NT$688.84 Million ≈ $21.70 Million |
+11.81% |
| 2021-12-31 | NT$616.07 Million ≈ $19.41 Million |
-4.45% |
| 2020-12-31 | NT$644.77 Million ≈ $20.31 Million |
+2.93% |
| 2019-12-31 | NT$626.44 Million ≈ $19.74 Million |
+2.72% |
| 2018-12-31 | NT$609.85 Million ≈ $19.21 Million |
+2.31% |
| 2017-12-31 | NT$596.06 Million ≈ $18.78 Million |
+7.44% |
| 2016-12-31 | NT$554.77 Million ≈ $17.48 Million |
+5.32% |
| 2015-12-31 | NT$526.73 Million ≈ $16.59 Million |
+62.38% |
| 2014-12-31 | NT$324.37 Million ≈ $10.22 Million |
+190.16% |
| 2013-12-31 | NT$111.79 Million ≈ $3.52 Million |
-24.24% |
| 2012-12-31 | NT$147.57 Million ≈ $4.65 Million |
-19.28% |
| 2011-12-31 | NT$182.81 Million ≈ $5.76 Million |
+18.73% |
| 2010-12-31 | NT$153.96 Million ≈ $4.85 Million |
-39.10% |
| 2009-12-31 | NT$252.83 Million ≈ $7.97 Million |
-42.39% |
| 2008-12-31 | NT$438.89 Million ≈ $13.83 Million |
-37.47% |
| 2007-12-31 | NT$701.86 Million ≈ $22.11 Million |
-7.36% |
| 2006-12-31 | NT$757.63 Million ≈ $23.87 Million |
-4.23% |
| 2005-12-31 | NT$791.11 Million ≈ $24.92 Million |
+3.23% |
| 2004-12-31 | NT$766.35 Million ≈ $24.14 Million |
-0.49% |
| 2003-12-31 | NT$770.15 Million ≈ $24.26 Million |
+0.55% |
| 2002-12-31 | NT$765.96 Million ≈ $24.13 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was fou… Read more